Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.

Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.

Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.

View all videos

ASH 2020

American Society of Hematology (ASH) Annual Meeting and Exposition
5–8 December 2020
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Scott J. Rodig discusses checkpoint inhibitors

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390341862121250817Retweet on Twitter 13903418621212508171Like on Twitter 13903418621212508171Twitter 1390341862121250817
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Francisco J. Hernandez-Ilizaliturri discusses IMiDs in combination

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390339388526243842Retweet on Twitter 1390339388526243842Like on Twitter 1390339388526243842Twitter 1390339388526243842
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Frederick Locke discusses how tumor IFN signaling and suppressive myeloid cells impact CAR T-cell efficacy

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390336867804004354Retweet on Twitter 1390336867804004354Like on Twitter 1390336867804004354Twitter 1390336867804004354
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Stephen Ansell discusses CBT in specific lymphoma subtypes

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390334327221858304Retweet on Twitter 13903343272218583041Like on Twitter 1390334327221858304Twitter 1390334327221858304
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Patricia Pérez Galán discusses the microenvironment in FL pathogenesis and therapy

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390331826921693186Retweet on Twitter 1390331826921693186Like on Twitter 1390331826921693186Twitter 1390331826921693186
Load More...

ASH 2020

American Society of Hematology (ASH) Annual Meeting and Exposition
5–8 December 2020

Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.

Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.

Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.

View all videos
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Scott J. Rodig discusses checkpoint inhibitors

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390341862121250817Retweet on Twitter 13903418621212508171Like on Twitter 13903418621212508171Twitter 1390341862121250817
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Francisco J. Hernandez-Ilizaliturri discusses IMiDs in combination

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390339388526243842Retweet on Twitter 1390339388526243842Like on Twitter 1390339388526243842Twitter 1390339388526243842
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Frederick Locke discusses how tumor IFN signaling and suppressive myeloid cells impact CAR T-cell efficacy

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390336867804004354Retweet on Twitter 1390336867804004354Like on Twitter 1390336867804004354Twitter 1390336867804004354
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Stephen Ansell discusses CBT in specific lymphoma subtypes

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390334327221858304Retweet on Twitter 13903343272218583041Like on Twitter 1390334327221858304Twitter 1390334327221858304
VJHemOncVJHemOnc@VJHemOnc·
2h

#iwNHL21: Patricia Pérez Galán discusses the microenvironment in FL pathogenesis and therapy

Click here for the in latest #Lymphoma: https://tinyurl.com/LymphomaNews

#Lymsm #NonHodgkinLymphoma @VJHemOnc

Reply on Twitter 1390331826921693186Retweet on Twitter 1390331826921693186Like on Twitter 1390331826921693186Twitter 1390331826921693186
Load More...
Myeloma Lymphoma RWD CLL AML CAR-T Transplant MRD MDS Trial Updates MPNs ALL

Latest Videos

View all
4:08
Inotuzumab ozogamicin for treating pediatric R/R ALL
Erica Brivio • 10 Dec 2020
2:03
Engineering multi-antigenic CAR T-cells for AML
Sara Ghorashian • 7 Dec 2020
1:05
Limitations of ibrutinib and ruxolitinib use in cGVHD
Carlos Bachier • 3 Dec 2020
1:55
CAR T-cell therapy for relapsed ALL with CNS involvement
Sara Ghorashian • 7 Dec 2020

Multiple Myeloma

View all
1:42
First-in-human trial of an anti-BCMA ADC for R/R myeloma
Meletios Dimopoulos • 5 Dec 2020
2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020

Lymphoma

View all
2:24
Blinatumomab consolidation therapy for DLBCL
John DiPersio • 8 Dec 2020
2:26
Pivotal findings at ASH 2020
Constantine Tam • 10 Dec 2020

CLL

View all
2:28
Accelerated venetoclax ramp-up for R/R CLL
Matthew Davids • 5 Dec 2020
8:04
The MURANO study in CLL: 5 years on
John Seymour • 7 Dec 2020

AML

View all
7:32
Current immune checkpoint inhibitor trials in AML/MDS
Amer Zeidan • 7 Dec 2020
2:43
SIERRA: Iomab-B for pre-HSCT AML
Sergio Giralt • 14 Dec 2020

CAR-T

View all
2:03
Engineering multi-antigenic CAR T-cells for AML
Sara Ghorashian • 7 Dec 2020
1:55
CAR T-cell therapy for relapsed ALL with CNS involvement
Sara Ghorashian • 7 Dec 2020

Transplant

View all
1:05
Limitations of ibrutinib and ruxolitinib use in cGVHD
Carlos Bachier • 3 Dec 2020
5:13
alloHCT: HLA-matched unrelated vs HLA-identical sibling donor for MDS
Guru Subramanian Guru Murthy • 17 Dec 2020

MDS

View all
2:19
Imetelstat for transfusion-dependent R/R MDS
Uwe Platzbecker • 17 Dec 2020
2:00
NKG2D CAR-T cell therapy in AML/MDS
David Sallman • 10 Dec 2020

MRD

View all
4:40
Lintuzumab-Ac225 and CLAG-M for R/R AML
Guru Subramanian Guru Murthy • 17 Dec 2020
4:59
Venetoclax plus CLAD/LDAC and aza for older AML patients
Tapan Kadia • 3 Dec 2020

MPNs

View all
4:34
PV highlights at ASH 2020
Prithviraj Bose • 11 Dec 2020
4:15
Updates in MPNs at ASH 2020
Aaron Gerds • 7 Dec 2020

ALL

View all
4:08
Inotuzumab ozogamicin for treating pediatric R/R ALL
Erica Brivio • 10 Dec 2020
1:55
CAR T-cell therapy for relapsed ALL with CNS involvement
Sara Ghorashian • 7 Dec 2020
Inotuzumab ozogamicin for treating pediatric R/R ALL 4:08
Inotuzumab ozogamicin for treating pediatric R/R ALL
Erica Brivio • 10 Dec 2020
Engineering multi-antigenic CAR T-cells for AML 2:03
Engineering multi-antigenic CAR T-cells for AML
Sara Ghorashian • 7 Dec 2020
Limitations of ibrutinib and ruxolitinib use in cGVHD 1:05
Limitations of ibrutinib and ruxolitinib use in cGVHD
Carlos Bachier • 3 Dec 2020
CAR T-cell therapy for relapsed ALL with CNS involvement 1:55
CAR T-cell therapy for relapsed ALL with CNS involvement
Sara Ghorashian • 7 Dec 2020
Real-world outcomes following tisa-cel for R/R ALL: an intention-to-treat analysis 1:56
Real-world outcomes following tisa-cel for R/R ALL: an intention-to-treat analysis
Sara Ghorashian • 7 Dec 2020
MURANO trial: duvelisib plus venetoclax in R/R CLL, SLL and Richter’s Syndrome 2:57
MURANO trial: duvelisib plus venetoclax in R/R CLL, SLL and Richter’s Syndrome
Jennifer Crombie • 8 Dec 2020
Challenges of selecting frontline therapy in CLL 12:15
Challenges of selecting frontline therapy in CLL
Jacqueline Barrientos • 10 Dec 2020
VLS-101: an ADC for MCL and DLBCL 1:51
VLS-101: an ADC for MCL and DLBCL
Jacqueline Barrientos • 10 Dec 2020
Key takeaways from ASH 2020 in multiple myeloma 4:41
Key takeaways from ASH 2020 in multiple myeloma
Thomas Martin • 10 Feb 2021
alloHCT: HLA-matched unrelated vs HLA-identical sibling donor for MDS 5:13
alloHCT: HLA-matched unrelated vs HLA-identical sibling donor for MDS
Guru Subramanian Guru Murthy • 17 Dec 2020
Lintuzumab-Ac225 and CLAG-M for R/R AML 4:40
Lintuzumab-Ac225 and CLAG-M for R/R AML
Guru Subramanian Guru Murthy • 17 Dec 2020
Biologic and clinical progression in hematological malignancies at ASH 2020 4:36
Biologic and clinical progression in hematological malignancies at ASH 2020
Arnon Nagler • 9 Dec 2020
CD19-CAR-T therapy for CLL with Richter’s transformation 2:12
CD19-CAR-T therapy for CLL with Richter’s transformation
Arnon Nagler • 9 Dec 2020
Venetoclax plus CLAD/LDAC and aza for older AML patients 4:59
Venetoclax plus CLAD/LDAC and aza for older AML patients
Tapan Kadia • 3 Dec 2020
Allogeneic cord blood Treg infusion for BMF syndromes 5:37
Allogeneic cord blood Treg infusion for BMF syndromes
Tapan Kadia • 3 Dec 2020
Impact of MRD-negativity on outcomes in the FORTE myeloma trial 4:05
Impact of MRD-negativity on outcomes in the FORTE myeloma trial
Stefania Oliva • 8 Dec 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals